The aim of this study was to evaluate the efficacy and safety of 2 high-dose treatment regimens of ampicillin-sulbactam (A/S) for MDR Acinetobacter baumannii ...

23 февр. 2017 г. · In 24-h time-kill experiments, high-dose ampicillin-sulbactam in combination with meropenem and polymyxin B achieved additivity or synergy against 10 8 CFU/ml ...

23 февр. 2017 г. · Acinetobacter baumannii is emerging with resistance to polymyxins. In 24-h time-kill experiments, high-dose ampicillin-sulbactam in ...

Extended Infusion Dosing (if recommended by ID or ID pharmacy) ; Carbapenem-resistant Acinetobacter baumannii. 9 gram IV q 8h (over 4 hours). 6 grams IV q 8h ( ...

Conclusion. Colistin and high-dose ampicillin/sulbactam were comparably safe and effective treatments for critically ill patients with MDR A. baumannii VAP.

Acinetobacter baumannii is emerging with resistance to polymyxins. In 24-h time-kill experiments, high-dose ampicillin-sulbactam in combination with ...

24 авг. 2023 г. · At a sulbactam MIC value of 16 mg/L, higher ampicillin-sulbactam doses of 9 g every 8 hours (sulbactam 9 g/d) administered by 4-hour infusions ...

8 июл. 2009 г. · In summary, our study indicates that high-dose regimen of ampicillin/sulbactam could be an alternative and safe treatment option for MDR A.

However, sulbactam could be maximized in a dosage as high as 12 g daily with prolonged or continuous infusion, especially in treatment of critically ill ...

30 нояб. 2016 г. · Clinical improvement was observed in 69.1% of the patients, 15.3% died within 14 days, and 28-day mortality was 30.0%. The clinical outcome of ...